Gilead Sciences, Inc. (GILD) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Foster City, CA, United States. The current CEO is Daniel O'Day.
GILD has IPO date of 1992-01-22, 17,600 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $174.33B.
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, that discovers, develops, and commercializes innovative medicines addressing unmet medical needs across the United States, Europe, and international markets. The company's portfolio spans multiple therapeutic areas, including HIV/AIDS treatment with leading antiretroviral products such as Biktarvy and Truvada, hepatitis C and liver disease management through Epclusa and Harvoni, oncology and cell therapy with products like Yescarta and Trodelvy, and other critical care areas including pulmonary arterial hypertension and serious fungal infections. Gilead also gained prominence for Veklury, its antiviral treatment for COVID-19. The company maintains strategic collaboration agreements with numerous leading biopharmaceutical and research organizations to advance its pipeline and expand its therapeutic capabilities.
